Business Case

Revised value proposition to support launch of a small molecule in a second indication

Our client, a mid-size pharmaceutical company was looking to launch its flagship asset into a 2nd indication, for Parkinson’s Disease and needed assistance developing materials to support the expanded indication. LSC collaborated to craft a revised value proposition and commercial model tailored to the new indication. The result was an optimized launch strategy, reinforced by a comprehensive stakeholder engagement plan, positioning the drug effectively in the Parkinson’s Disease market.